Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Drugs and treatments for inflammatory diseases are scarce and often induce major side effects. A better understanding of the molecular mechanisms governing inflammatory diseases would allow us to develop new drug and treatments, at great benefit for both patients and the NHS.

Q: What are inflammatory diseases?

Luzheng Xue: To answer this question we have to start from inflammation. Inflammation is the body's normal immune response to something we believe is harmful.

Sometimes, the immune system malfunctions and attacks some harmless substance such as pollen or peanuts, and this causes an allergic inflammation. Sometimes, the body itself (tissues and cells) are attacked, and this is called autoimmune disease. These abnormal reactions and the subsequent symptoms cause inflammatory disease.

Q: What is the specific focus of your own work?

LX: We try to develop new drugs and a new method to control and treat inflammatory diseases. For example, in collaboration with a pharmaceutical company called Atopix Therapeutics, we try to target asthma and atopic dermatitis. We are also working together with Orca Pharmaceuticals to try and target autoimmune disease. We screen new drugs and then work out how these drugs are working and how to best use them.

Q: Can you give us an example of how your work is beginning to make a change to how patients are treated?

LX: For example, currently we are working on a new drug, and this drug is already in the late stage of clinical trials. In the clinical trial it already shows some benefits for the treatment of asthma. We have also found another new drug, in collaboration with Orca Pharmaceuticals and this drug can potentially be used to treat autoimmune disease.

Q: What are the most important lines of research that have developed in the field in the last 5-10 years?

LX: The most important line of research developed in our group in recent years is trying to understand the role of the prostaglandin receptors. These receptors are present on some immune cell surface and are involved in the allergic response. We can try to find out the mechanisms and then develop new drugs; this is potentially a very promising drug target.

We also trying to work on another receptor that is located in the nucleus: this (receptor) controls the development of immune cells which lead to autoimmune disease. So this is potentially also another good drug target.

Q: Why does this line of research matter and why should we fund it?

LX: Something like asthma or psoriasis is very difficult to treat. These illnesses poorly respond to current therapies. Even if some (like steroids) do work, they will have side effects. This kind of situation significantly reduces the quality of life for patients. These therapies are also a heavy burden on NHS resources.

So in our studies, we are trying to develop a new drug or a new treatment that can control this disease. This will benefit patients as well as the NHS, so its likely to be very useful in future.

Q: How does your work fitin to translational medicine within the department?
LX: Our research allows us to understand the mechanism of inflammatory disease. This then help us develop new treatments or new drugs to treat these diseases: a great benefit to the patients. Therefore our studies directly lead to medical applications, and that is exactly what translational medicine needs to do.

Luzheng Xue

The main aim of Dr Xue's research is to understand the molecular and cellular mechanisms mediating inflammatory diseases, and to translate their findings into therapeutic concepts to treat these diseases.

More podcasts related to Translational & Clinical

David Stuart: Structural biology and vaccines

The basis of an effective vaccine is that a pathogen is physically recognised by the immune system.

Kay Grunewald: Structural cell biology of virus infection

Understanding the entirety of a virus’ ‘life cycle’ requires an understanding of its transient structures at the molecular level. Using imaging techniques allows us to understand the communication between the virus and the components of the cell it is infecting, which can ultimately help to treat infectious diseases.

Jens Rittscher: Biological imaging

Video microscopy aims to improve target discovery and drug development and to do so generates large volumes of data. Fluorescence labelling helps make intrinsic cellular functions visible and computational tools then enable analysis of these data sets to improve our understanding of cellular functions.

Sebastian Nijman: Pharmacogenomics

In the context of cancer, genetic diversity means that we respond differently to various treatments. Pharmacogenomics sits at the intersection between genetics and drugs. Better understanding of the genetic landscape of cancer and the recent increase of targeted drugs allow us to better match patients with the best treatments, improving care.

Ian Pavord: Asthma

Ian Pavord's research in to airway inflammation has resulted in mepolizumab being identified as an effective inhibitor of eosinophilic inflammation and asthma attacks. Mepolizumab is currently in Phase III clinical trials and if found to be effective could be a promising treatment for certain asthma patients.

Trudie Lang: The Global Health Network

The Global Health Network is a successful and growing online science park comprised of varied research communities for different health research groups and cross-cutting health topics. It is built for the research and wider health community by researchers and public health practitioners themselves. It is a trusted source of quality information, education and research tools.

Najib Rahman: Respiratory Medicine

Respiratory medicine encompasses a large number of common diseases like pneumonia, asthma, emphysema and lung cancer. Outcomes are currently relatively poor and the area of research is underfunded. Recent progress have been made towards personalising treatment, and Dr Rahman's research aims at improving patient care.

Chris O’Callaghan: Atherosclerosis & immunity

Atherosclerosis is the most important cause of death worldwide. It is caused by the accumulation of both fatty material and immune cells. Over time, these set up an inflammatory reaction which causes a lot of damage to the blood vessel wall. Although we do have good therapies designed to lower the levels of fatty material, we haven’t any therapies specifically designed to target the effect of the immune system. Professor O'Callaghan's group is working towards developing such therapies.

Stefan Knapp: Development of chemical probes

While drugs were initially developped by testing natural products directly in humans, the current approach is to use chemical probes. These are small chemical coumpounds that inhibit selected targets, avoiding side effects. Professor Knapp produces structures of molecular targets and makes them widely available. This will allow a faster and more cost effective development of new drugs.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.